Twist Bioscience officer proposes $1.97M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Twist Bioscience Corp (TWST) officer and director Emily M. Leproust reported a proposed sale of 19,045 common shares, with an aggregate market value of $1,974,745.58 and an approximate sale date of November 16, 2026. The shares were acquired through restricted stock vesting on November 12, 2026; the notice says the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution. It also lists prior sales, including 356,546 shares sold for gross proceeds of $56,330,878.38 on September 17, 2026.
Key Figures
Key Terms
Restricted Stock Vesting financial
vested equity award distribution financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.